FAQ

EGFR Inhibitor HM61713

Known as: HM61713 
An orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
024620142018

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Related mentions per year

Related mentions per year

2010-2018
201020122014201620182020
EGFR Inhibitor HM61713
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
EGFR T790M mutation leads to resistance to most of clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M… (More)
Is this relevant?
2017
2017
Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
 
Is this relevant?
Review
2017
Review
2017
Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
PURPOSE OF REVIEW The most common mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors… (More)
  • figure 1
Is this relevant?
2016
2016
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
T790M mutation is most common resistant mechanism to epidermal growth factor receptor gene (EGFR) tyrosin kinase inhibitor (TKI… (More)
Is this relevant?
2016
2016
190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine…
effusion. There were 410 male and 120 female, with a mean age of 54 years. In 401 patients VATS was performed under general… (More)
Is this relevant?
Review
2016
Review
2016
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2016
Review
2016
Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyrosine kinase inhibitors (TKIs… (More)
  • table 2
  • table 3
  • table 3
  • figure 1
  • table 4
Is this relevant?
2016
2016
1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose.
 
Is this relevant?
Review
2016
Review
2016
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
PURPOSE OF REVIEW Patients with epidermal growth factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC… (More)
Is this relevant?
Review
2015
Review
2015
Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era?
EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line treatment for non-small-cell lung… (More)
  • table 1
  • table 2
  • table 4
  • table 5
  • figure 1
Is this relevant?